Lipocine (NASDAQ:LPCN) Stock Passes Above 50 Day Moving Average – What’s Next?

Lipocine Inc. (NASDAQ:LPCN) crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $2.28 and traded as high as $2.56. Lipocine shares last traded at $2.34, with a volume of 159,254 shares trading hands.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on LPCN shares. Weiss Ratings restated a “sell (d-)” rating on shares of Lipocine in a report on Friday, March 27th. HC Wainwright reiterated a “neutral” rating on shares of Lipocine in a research note on Monday, April 6th. Finally, Wall Street Zen lowered shares of Lipocine from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Lipocine has a consensus rating of “Hold” and a consensus price target of $15.00.

Lipocine Stock Performance

The firm has a market capitalization of $19.28 million, a price-to-earnings ratio of -1.25 and a beta of 0.48. The business’s 50 day moving average is $2.28 and its 200-day moving average is $5.54.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.03). The company had revenue of $0.12 million during the quarter, compared to analyst estimates of $0.16 million. Lipocine had a negative return on equity of 66.70% and a negative net margin of 571.18%. Equities research analysts forecast that Lipocine Inc. will post -1.91 EPS for the current fiscal year.

Insider Activity

In other Lipocine news, CEO Mahesh V. Patel bought 25,000 shares of the firm’s stock in a transaction dated Monday, April 6th. The shares were acquired at an average cost of $2.03 per share, for a total transaction of $50,750.00. Following the transaction, the chief executive officer owned 160,679 shares in the company, valued at approximately $326,178.37. The trade was a 18.43% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director John W. Higuchi bought 40,000 shares of the firm’s stock in a transaction dated Tuesday, April 7th. The shares were acquired at an average price of $2.03 per share, for a total transaction of $81,200.00. Following the completion of the transaction, the director owned 203,797 shares in the company, valued at $413,707.91. This represents a 24.42% increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have bought 213,000 shares of company stock worth $434,600. 6.35% of the stock is owned by company insiders.

Institutional Trading of Lipocine

Several institutional investors have recently made changes to their positions in LPCN. Citadel Advisors LLC acquired a new stake in shares of Lipocine during the 3rd quarter valued at about $41,000. Geode Capital Management LLC boosted its position in shares of Lipocine by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock valued at $502,000 after acquiring an additional 1,374 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Lipocine by 3.6% during the 4th quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock valued at $300,000 after purchasing an additional 1,300 shares during the last quarter. Jane Street Group LLC bought a new position in Lipocine during the 4th quarter valued at about $85,000. Finally, Persistent Asset Partners Ltd bought a new position in Lipocine during the 4th quarter valued at about $567,000. 9.11% of the stock is currently owned by institutional investors and hedge funds.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.